Outset Medical(US:OM) Globenewswire·2025-12-30 21:21Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Outset Medical and its officers/directors, following disappointing financial results and a significant drop in stock price [1][3]. Financial Performance - On November 10, 2025, Outset Medical reported non-GAAP earnings per share of -$0.69, missing consensus estimates by $0.03 [3]. - The company generated revenue of $29.43 million for the third quarter of 2025, which was $1.27 million below consensus estimates [3]. - Outset Medical revised its 2025 revenue outlook to a range of $115 million to $120 million, down from a previous range of $122 million to $126 million, citing delays in closing large opportunities [3]. Stock Market Reaction - Following the announcement of the financial results, Outset Medical's stock price fell by $5.85 per share, or 48.47%, closing at $6.22 per share on November 11, 2025 [3].